Skip to Main Content

COVID-19 is an emerging, rapidly evolving situation.

What people with cancer should know: https://www.cancer.gov/coronavirus

Get the latest public health information from CDC: https://www.coronavirus.gov

Get the latest research information from NIH: https://www.nih.gov/coronavirus

Purpose

Throughout the Etiologic and Early Marker Studies (EEMS) existence, several studies have measured various sex hormones in blood serum. For CDAS, these measurements are available in separate datasets corresponding to each study for which they were originally selected.

Population

These studies were each selected at different time points, using a different set of exclusions and matching criteria. For all studies, the common requirements for inclusion were etiologic consent, serum availability, intervention arm, a baseline questionnaire, some form of follow-up within the trial, and no history of the site-specific cancer prior to blood collection. All studies used blood collected at T0, except for the upper GI study and 2nd endometrial study, where the first available pre-diagnostic collection was used. For all studies except for breast and prostate, the set of cases were matched directly to the controls. For breast and prostate, however, the populations were the subsets of the Breast and Prostate Cancer Cohort Consortium (BPC3) study and the Cancer Genetic Markers of Susceptibility (CGEMS) study who had available serum.

Site Non-Common Inclusion Criteria Matching Variables Cases Non-Cases
Prostate
  • White
  • Male
  • With a Prostate Cancer Screen
  • Age at Randomization (5 Years)
  • First Year of Blood Draw
  • Study Year of Dx/Selection
729 841
Breast
  • Females
  • No non-breast cancers during trial
  • Not Current HRT User
  • Age at Randomization (5 Years)
  • Fiscal Year of Randomization (<=1997, 1998+)
382 460
Endometrial
  • No Cancer at Baseline
  • Females
  • Defined Hormone Use
  • No Hysterectomy
  • Controls known to be post-menopausal
  • Race
  • Age at Randomization (5 Years)
  • Study Center
  • Hormone Use
  • Year of Blood Draw
  • Time of Day of Blood Draw (am/pm)
  • Study Year of Dx/Selection
171 339
2nd Prostate
  • White
  • Male
  • Not from Hawaii Study Center
  • In Prostate BPC3 Biochemical Pop.
  • Advanced Cases Only
  • Controls have BPC3 Results
  • Age at Randomization (5 Years)
  • Year of Blood Draw
  • Study Year of Dx/Selection
195 195
2nd Endometrial
  • No Cancer at Baseline
  • Females
  • Controls Cancer-free through
  • Follow-up
  • No Hysterectomy
  • Age at Randomization (5 Years)
  • Fiscal Year of Randomization
  • Race (white/non-white)
  • Study Year of Blood Draw
  • Study Year of Dx/Selection
283 283
Upper GI
  • No Cancer at Baseline
  • Gastric Cases Limited to Males
  • Gender
  • Race
  • Age at Blood Draw (+/- 1 Year)
  • Study Year of Blood Draw
  • Year of Blood Draw
  • Time of Day of Blood Draw (am/pm)
101 101

Data Collected

Below is a table of the analytes measured in each study.

Prostate Breast Endometrial 2nd Prostate 2nd Endometrial Upper GI
Androstenedione X
Sex Hormone-Binding Globulin X X
Testosterone X
Estrone X X
Estradiol X X X X
Estriol X X
16-Epiestriol X X
16-Ketoestradiol X X
2-Methoxyestrone X X
2-Hydroxyestrone-3-Methyl Ether X X
4-Methoxyestrone X X
2-Methoxyestradiol X X
4-Methoxyestradiol X X
16a-Hydroxyestrone X X
2-Hydroxyestrone X X
4-Hydroxyestrone X X
2-Hydroxyestradiol X X
Androstenediol X

Sex Hormones data can be obtained in the Sex Hormones datasets

Main Findings